Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Gilead Sciences's Q1 2026 Earnings: What to Expect

Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $173 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.

GILD is expected to release its Q1 2026 earnings soon. Ahead of the event, analysts expect the company’s EPS to be $1.86 on a diluted basis, up 2.8% from $1.81 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in...

Fundamentals

See More
  • Market Capitalization, $K 174,143,456
  • Shares Outstanding, K 1,241,222
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,022 M
  • EBITDA $ 12,782 M
  • 60-Month Beta 0.39
  • Price/Sales 5.88
  • Price/Cash Flow 13.02
  • Price/Book 7.48

Options Overview Details

View History
  • Implied Volatility 31.75% (-0.07%)
  • Historical Volatility 22.73%
  • IV Percentile 64%
  • IV Rank 36.16%
  • IV High 49.97% on 04/08/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 8) 4.42 (3.15%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 2,190
  • Volume Avg (30-Day) 12,613
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 151,684
  • Open Int (30-Day) 152,238
  • Expected Range 135.88 to 144.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.86
  • Number of Estimates 9
  • High Estimate $1.97
  • Low Estimate $1.73
  • Prior Year $1.81
  • Growth Rate Est. (year over year) +2.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.89 +5.00%
on 03/30/26
149.38 -5.89%
on 03/10/26
-9.45 (-6.30%)
since 03/02/26
3-Month
116.88 +20.28%
on 01/05/26
157.29 -10.62%
on 02/11/26
+18.98 (+15.61%)
since 01/02/26
52-Week
93.37 +50.56%
on 04/25/25
157.29 -10.62%
on 02/11/26
+28.69 (+25.64%)
since 04/02/25

Most Recent Stories

More News
Gilead Extends Tender Offer to Acquire Arcellx

Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00...

GILD : 139.86 (-0.31%)
Gilead Sciences's Q1 2026 Earnings: What to Expect

Gilead Sciences is expected to announce its first-quarter results soon, and analysts are projecting single-digit EPS growth.

XLV : 147.08 (-0.44%)
$SPX : 6,575.32 (+0.72%)
GILD : 139.86 (-0.31%)
Options Action: Naked Put Trade Ideas for March 31

With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener.

INTC : 47.27 (-1.58%)
MU : 341.65 (-7.12%)
FCX : 59.46 (-2.84%)
GILD : 139.86 (-0.31%)
DAL : 64.48 (-4.62%)
S&P Futures Waver as Concerns Over Middle East Conflict Persist, U.S. PMI Data in Focus

June S&P 500 E-Mini futures (ESM26) are trending up +0.02% this morning, swinging between gains and losses as optimism over a de-escalation in the Middle East conflict wanes.

APO : 106.59 (-3.32%)
AVGO : 302.33 (-3.56%)
JEF : 40.40 (-2.32%)
CCL : 25.08 (-5.64%)
ASML : 1,298.67 (-4.49%)
FICO : 1,057.93 (-0.38%)
ESM26 : 6,529.25 (-1.34%)
CRWV : 74.71 (-4.76%)
TSLA : 366.30 (-3.92%)
NCLH : 18.41 (-5.01%)
PUIG.E.DX : 17.265 (-0.43%)
RL : 343.20 (-2.78%)
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio -- -- Gilead Intends...

GILD : 139.86 (-0.31%)
3 Reasons to Avoid GILD and 1 Stock to Buy Instead

3 Reasons to Avoid GILD and 1 Stock to Buy Instead

GILD : 139.86 (-0.31%)
2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

META : 561.89 (-2.99%)
TSLA : 366.30 (-3.92%)
GILD : 139.86 (-0.31%)
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Arcellx , Inc....

ACLX : 114.72 (-0.03%)
GILD : 139.86 (-0.31%)
3 Top-Rated Stocks to Buy to Hedge Against Stagflation as Middle East Conflict Drags On

Amid widespread uncertainties, these three names can shield your portfolio.

KO : 76.73 (+0.85%)
GILD : 139.86 (-0.31%)
ET : 19.15 (+0.68%)
3 Blue-Chip Stocks Built for a Rotating Market

Investors are rotating out of overvalued mega-cap tech as the broader economy heats up; these three blue-chip stocks are attracting attention

DUK : 132.54 (+1.25%)
GILD : 139.86 (-0.31%)
HSY : 202.75 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 144.26
2nd Resistance Point 142.87
1st Resistance Point 141.59
Last Price 139.86
1st Support Level 138.92
2nd Support Level 137.53
3rd Support Level 136.25

See More

52-Week High 157.29
Last Price 139.86
Fibonacci 61.8% 132.87
Fibonacci 50% 125.33
Fibonacci 38.2% 117.79
52-Week Low 93.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.